- Home
- HMST vs TIL Comparison
HMST vs TIL Comparison
Compare HMST & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- TIL
- Stock Information
- Founded
- HMST 1921
- TIL 2018
- Country
- HMST United States
- TIL United States
- Employees
- HMST N/A
- TIL N/A
- Industry
- HMST Major Banks
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- TIL Health Care
- Exchange
- HMST Nasdaq
- TIL Nasdaq
- Market Cap
- HMST 169.7M
- TIL 171.7M
- IPO Year
- HMST 2012
- TIL 2021
- Fundamental
- Price
- HMST $10.90
- TIL $15.46
- Analyst Decision
- HMST Hold
- TIL Buy
- Analyst Count
- HMST 3
- TIL 5
- Target Price
- HMST $14.50
- TIL $114.00
- AVG Volume (30 Days)
- HMST 314.2K
- TIL 78.2K
- Earning Date
- HMST 04-29-2025
- TIL 05-09-2025
- Dividend Yield
- HMST N/A
- TIL N/A
- EPS Growth
- HMST N/A
- TIL N/A
- EPS
- HMST N/A
- TIL N/A
- Revenue
- HMST $75,702,000.00
- TIL N/A
- Revenue This Year
- HMST $163.76
- TIL N/A
- Revenue Next Year
- HMST $7.69
- TIL N/A
- P/E Ratio
- HMST N/A
- TIL N/A
- Revenue Growth
- HMST N/A
- TIL N/A
- 52 Week Low
- HMST $8.09
- TIL $9.62
- 52 Week High
- HMST $16.10
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- HMST 55.32
- TIL 44.19
- Support Level
- HMST $10.16
- TIL $14.96
- Resistance Level
- HMST $11.23
- TIL $18.71
- Average True Range (ATR)
- HMST 0.82
- TIL 1.80
- MACD
- HMST -0.03
- TIL 0.09
- Stochastic Oscillator
- HMST 30.33
- TIL 46.32
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.